简介：Objective:Langerhanscellhistiocytosis(LCH)hasbeenwelldescribedonlyinchildren.Weanalyzedthecharacteristics,reactivation,andoutcomeofLCHinacohortof55patientsacrossallages.Methods:WereviewedtherecordsofallpatientswithLCHtreatedatasingleinstitutebetweenJan.1974andMay1998.Results:The55patientswere2to67yearsofage(median,31years)atthetimeofdiagnosis,and85.5%weremale.Fortypatients(72.7%)hadsingle-systemLCH;Fifteen(27.3%)hadmultisystemdisease.Theheadandneckwasthemostfrequenttumorsite(63.6%).LCHwasnotfoundinorgansatriskofinvolvement(liver,spleen,bonemarrow,andlungs).Thefrequencyofbonyinvasion(23.6%overall)differedsignificantlyaccordingtoage(15years(66.7%)vs.Age>15years(11.6%)(P=0.0005).Atamedianfollow-upof12years,nopatientdiedofLCH.The5,10-yearsurvivalestimateswere100%.The5,10-yeardisease-freesurvivalestimateswere70.9%and58.4%.The5-yeardisease-freesurvivalestimatewas58.3%forage(15yearsvs.74.4%forage>15years(P=0.83)and75%forsingle-systemdiseasevs.60%formultisystemdisease(P=0.13).LCHwasreactivatedin43.6%ofpatients,withamedianof14months(range,2-180months).Threepatientswithrecurrentdiseaseexperiencedspontaneousremission.Atthetimeofthemostrecentfollow-up,23.6%ofsurvivorshadactivedisease.Conclusion:LCHisnotfoundexclusivelyinchildrenandadolescents.Thefrequencyofboneinvasionisinverselyrelatedtoage.Reactivationisverycommonregardlessofthetypeoftreatment,buttheprognosisisgenerallygood.

简介：目的探讨乳腺癌组织乙醛脱氢酶1（ALDH1）阳性表达及CD55高表达在乳腺癌患者预后评估中的价值。方法应用免疫组化法对65例随访5～8年的乳腺癌患者的组织标本进行ALDHl和CD55表达检测，判定ALDH1阳性表达及CD55高表达标本，分析各临床疾病特征与CD55高表达及ALDH1阳性表达的关系。计算患者的5年生存率，分析其与CD55高表达、ALDH1阳性的相关性；分析5年生存率与临床疾病特征的相关性，并进一步筛选影响患者预后的独立危险因素。结果65例乳腺癌组织标本中，ALDH1阳性表达占24．6％（16／65），CD55高表达占33．8％（22／65）。ALDH1阳性表达和CD55高表达与乳腺癌患者绝经状况、肿瘤组织学类型、组织学分级、肿瘤直径、是否发生淋巴结转移、雌激素受体和孕酮受体表达情况、表皮生长因子受体2（Her2）表达情况、术后是否接受其他治疗均无关（P〉0．05），与肿瘤是否复发密切相关（氏0．01）。与ALDHI阴性、CD55低表达患者相比，ALDH1阳性表达、CD55高表达患者的5g生存率显著降低（P〈0．001）。Logistic回归分析显示，ALDH1阳性表达、CD55高表达、肿瘤直径（〉5cm）、组织学分级（III级）、Her2表达阴性、术后未接受治疗是影响乳腺癌患者预后的独立因素。结论乳腺癌组织ALDH1阳性表达和CD55高表达可能是与乳腺癌患者预后相关的独立影响因素。